Maricel Mojares-Moore

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Talkiatry, a top provider of high-quality, in-network psychiatric care, on its $130 million equity and debt financing round.

Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.

Cooley advised Poseida Therapeutics, a clinical-stage biopharmaceutical company, on its strategic collaboration and license agreement with Roche. Lawyers Ken Krisko, Marya Postner, Bin Wang, Hajra Nashin and Brendan Haberle led the Cooley team advising Poseida. 

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.